Prostatitis Report



Physician Information

Patient, Name

Age/Sex: **54/M** DOB: **01/01/1970** Phone#: **123-456-7890** Medical Rec#: **12345**

Sample Physician MD Sample Location Address Line 1 City, CA 12345 Phone : 999.123.4567 Fax : 999.123.4568

Accession#: **TP24-00014** Date Collected: **03/26/2024** Date Received: **03/27/2024** Date Reported: **03/27/2024** Specimen: **Post Prostate Massage Urine** ICD 10: **N12.3**

Sample Information

Results: Positive

ORGANISM(S) - DETECTED

Escherichia coli

≥100000 CFU/ml

Report Key S = Sensitivity Detected R = Resistance Detected N = No Reference RGD = Resistance Gene(s) Detected	Amoxicillin / Clavulanate	Ampicillin	Cefaclor	Cephalexin	Ciprofloxacin	Doxycycline	Fosfomycin	Levofloxacin	Nitrofurantoin	Sulfamethoxazole/Trimethoprim	Amikacin	Ceftriaxone	Gentamicin	Imipenem	Cefazolin	Cefepime	Cefoxitin	Ceftazidime / Avibactam	Meropenem	Piperacillin / Tazobactam	Penicillin G	Vancomycin
Formulation	PO	PO/IV	PO	PO	PO/IV	PO/IV	РО	PO/IV	PO	PO/IV	IV/IM	IM/IV	IM/IV	IV	IV	IV	IV	IV	IV	IV	IV	IV
Sensitivity result:																						
Escherichia coli	s	s	s	s	s	s	s	s	s	s	s	s	s	s	s	s	s	s	s	s	R	R
Resistant Gene result :																						
Organism(s) Tested-De	tect	ed:			= P	lus n	nark	s are	sup	port	tive o	data	and	are	NOT	pati	ent	spec	ific			
Escherichia coli	+				+		+	ŧ	+		+	ŧ	÷	+	ł	+	ŧ	ŧ	+	+		

Information about the table:

Green PlusMarks indicate there is supportive evidence that the antibiotic either FDA approved or off label can be used for treatment. PlusMark treatment options are not intended to be prescriptive for any specific patient. Appropriate judgement should be exercised by the attending physician before prescribing a course of treatment. N = No reliable antibiotic reference is available for the detected organism. If an organism is listed in the detected section but not reflected in the sensitivity result table, the organism is either fastidious or failed to grow in vitro and cannot be tested for antibiotic susceptibility.

PHENOTYPIC SENSITIVITY DETECTED: Amikacin(IV/IM), Amoxicillin / Clavulanate(PO), Ampicillin(PO/IV), Cefaclor(PO), Cefazolin(IV), Cefepime(IV), Cefoxitin(IV), Ceftazidime / Avibactam(IV), Ceftriaxone(IM/IV), Cephalexin(PO), Ciprofloxacin(PO/IV), Doxycycline(PO/IV), Fosfomycin(PO), Gentamicin(IM/IV), Imipenem(IV), Levofloxacin(PO/IV), Meropenem(IV), Nitrofurantoin(PO), Piperacillin / Tazobactam(IV), Sulfamethoxazole/Trimethoprim(PO/IV)

PHENOTYPIC RESISTANCE DETECTED: Penicillin G(IV), Vancomycin(IV)

ANTIBIOTIC RESISTANCE GENES NOT DETECTED: Vancomycin Resistant (Glycopeptic antibiotics), Extended-Spectrum-B-Lactamase*, Methicillin Resistance, Quinolone and Fluoroquinolone Resistance, Sulfonamides Resistance

ORGANISM(S) - NOT DETECTED

Bacteria: Acinetobacter baumannii, Actinobaculum schaalii, Aerococcus urinae, Alloscardovia omnicolens, Citrobacter freundii, Citrobacter koseri, Coagulase negative Staphylococcus**, Corynebacterium riegelii, Enterobacter aerogenes***, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Klebsiella oxytoca, Klebsiella pneumoniae, Morganella morganii, Mycoplasma hominis, Pantoea agglomerans, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus agalactiae, Ureaplasma urealyticum, Viridans Group Streptococci****

FUNGUS: Candida albicans, Candida auris, Candida glabrata, Candida parapsilosis

• Testing performed at 12 Spectrum Pointe Drive Lake Forest, CA 92630 | Medical Director: Mr. Test, QC



Patient Name

Patient, Name

Procedure Date 03/26/2024

References:

* Extended Spectrum Beta-Lactamase (ESBL) Resistant genes identified confers resistance across multiple classes of antibiotics including Penicillin derivatives, cephalosporins, monobactams and carbapenems. Refer to the "Resistant Gene Detected" row to identify antibiotics for which the resistance gene may impact. Different ESBLs resistant genes will impact different beta lactam antibiotics in different levels and it is considered in the "Resistant Gene Detected" row for both ESBL (extended-spectrum β-lactamase) and BSBL (broad-spectrum βlactamase).

** Coagulase Negative Staphylococcus includes Staphylococcus saprophyticus, Staphylococcus epidermidis, Staphylococcus haemolyticus. *** Klebsiella aerogenes (formerly known as Enterobacter aerogenes)

**** Viridans Streptococci group includes Streptococcus anginosus, Streptococcus oralis and Streptococcus pasteurianus, Streptococcus mitis.

Methodology and Clinical Significance: Laboratory utilizes PCR amplification for the targeted detection of the specified organisms. Detected organisms are reported based on their percentage to the total detected organisms. Detected resistance genes are shown as RGD (Resistance Gene Detected) in the report table. In addition, phenotypic antibiotic susceptibility results are ascertained for the detected organism(s) by employing disk diffusion as a reference method for susceptibility. Antibiotic susceptibility testing is not performed for yeasts or fastidious organisms. For full methodology visit www.emeritusdx.com/methodology.

Disclaimer: This test was developed and its performance characteristics determined by laboratory. It has not been cleared or approved by the US Food and Drug Administration. The FDA has determined that such clearance or approvals is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical testing.

Final Report signed by EmeritusDX Test on 03/27/2024 at 09:44 AM

• Testing performed at 12 Spectrum Pointe Drive Lake Forest, CA 92630 | Medical Director: Mr. Test, QC